Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Prostate Cancer Metastatic 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Temozolomide 5anlotinib 43-Iodobenzylguanidine 4lutetium Lu 177 dotatate 3Specimen Handling 3cabozantinib 2belzutifan 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Everolimus 2Axitinib 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2tipifarnib 1talazoparib 1penpulimab 1pembrolizumab 1pazopanib 1olaparib 1lenvatinib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1fostamatinib 1copper dotatate CU-64 1atezolizumab 1Tamoxifen 1Sunitinib 1Ritonavir 1Octreotide 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pheochromocytoma × talazoparib × Clear all
NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡